Date: 2017-03-23
Type of information: Nomination
Compound:
Company: Retrophin (USA - CA)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 23, 2017, Retrophin announced the appointment of John A. Orwin to the Company's Board of Directors, effective immediately. Mr. Orwin is a biopharmaceutical industry veteran with more than 25 years of experience. He has served as chief executive officer of Relypsa since 2013. Previously, Mr. Orwin was chief executive officer and a director of Affymax. Before joining Affymax, Mr. Orwin held leadership positions in marketing, sales, and operations at Genentech , Johnson and Johnson, Alza Pharmaceuticals , Sangstat Medical Corporation , Rhone-Poulenc Rorer , and Schering-Plough . Mr. Orwin currently serves as a director of Seattle Genetics and Array BioPharma. Mr. Orwin earned a bachelor's degree from Rutgers University and master's degree in business administration from New York University .
Financial terms:
Latest news:
